UM Nobel Laureate Researcher Discovers Antioxidant Activity Of Growth Hormone-Releasing Hormone Antagonists (Medical News Today)
Researchers at the University of Miami Miller School of Medicine have discovered the antioxidant activity of growth hormone-releasing hormone (GHRH) antagonists in cancers. This discovery could lead to novel therapies against various cancers as well as neurodegenerative diseases, such as Alzheimer's. The results of the study, by Nobel laureate Andrew V. Schally, Ph.D., M.D.h.c., D.Sc.h.c.
Read more...
EU Requests WTO Consultations Concerning Hormone-Treated Beef (AG Weekly)
WASHINGTON (BUSINESS WIRE) - The European Union has requested consultations with the U.S. and Canada in the World Trade Organization concerning the WTO-compliance of its restrictions on hormone-treated beef.
Read more...
Fallout from EU import ban on hormone-treated beef continues after 10 years (North Queensland Register)
The European Union has begun new trade negotiations with the US, in an effort to persuade the US to lift sanctions imposed on EU imports into the US. These sanctions were introduced in retaliation of the EU's ban on the importation of all hormone-treated beef, 10 years ago.
Read more...
Fallout from EU import ban on hormone-treated beef continues (Queensland Country Life)
The European Union has begun new trade negotiations with the US, in an effort to persuade the US to lift sanctions imposed on EU imports into the US.
Read more...
FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) For Treatment Of Advanced Prostate Cancer (Medical News Today)
Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still under review with the FDA.
Read more...
|